Relay Therapeutics Stock Investor Sentiment

RLAY Stock  USD 4.75  0.11  2.37%   
Slightly above 56% of all Relay Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that some traders are interested. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Relay Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Relay Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a day ago at news.google.com         
Relay Therapeutics, Inc. Given Average Rating of Moderate Buy by Brokerages - MarketBeat
Google News at Macroaxis
2 days ago at zacks.com         
Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround
zacks News
3 days ago at finance.yahoo.com         
Down -23.95 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround
Yahoo News
3 days ago at thelincolnianonline.com         
Cornercap Investment Counsel Inc. Trims Holdings in Relay Therapeutics, Inc.
news
3 days ago at zacks.com         
Down -23.95 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround
zacks News
over a week ago at investing.com         
Relay Therapeutics SWOT analysis PI3K inhibitor progress fuels stock potential
Investing News at Macroaxis
over a week ago at investing.com         
Acquisition by Ingram Douglas S of 66055 shares of Relay Therapeutics at 11.14 subject to Rule 16b-3
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Relay Therapeutics Issues Earnings Results
news
over two weeks ago at globenewswire.com         
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Macroaxis News: globenewswire.com
over two weeks ago at zacks.com         
Stevanato Group Q3 Earnings Match Estimates
zacks News
over two weeks ago at thelincolnianonline.com         
Relay Therapeutics, Inc. CFO Thomas Catinazzo Sells 6,802 Shares
news
over three weeks ago at globenewswire.com         
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on Nove...
Macroaxis News: globenewswire.com
over three weeks ago at www.macroaxis.com         
Disposition of 2300 shares by Thomas Catinazzo of Relay Therapeutics at 5.95 subject to Rule 16b-3
Macroaxis News
over three weeks ago at finance.yahoo.com         
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.s recent US67m drop ad...
Yahoo News
over three weeks ago at finance.yahoo.com         
Disposition of 1632 shares by Adams Brian of Relay Therapeutics at 6.06 subject to Rule 16b-3
Yahoo News
Far too much social signal, news, headlines, and media speculation about Relay Therapeutics that are available to investors today. That information is available publicly through Relay media outlets and privately through word of mouth or via Relay internal channels. However, regardless of the origin, that massive amount of Relay data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relay Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relay Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relay Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relay Therapeutics alpha.

Relay Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Relay stock rallies 41 percent on positive data for RLY-2608
09/09/2024
2
Strength Seen in Relay Therapeutics Can Its 6.7 percent Jump Turn into More Strength
09/17/2024
3
Disposition of 1657 shares by Peter Rahmer of Relay Therapeutics at 11.16 subject to Rule 16b-3
09/23/2024
4
Disposition of 295 shares by Thomas Catinazzo of Relay Therapeutics at 7.51 subject to Rule 16b-3
10/01/2024
5
Biotech layoff tracker 13 biotechs cut over 1,400 jobs
10/02/2024
6
Short Interest in Relay Therapeutics, Inc. Grows By 24.7
10/15/2024
7
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.s recent US67m drop adds to long-term losses
10/28/2024
8
Disposition of 2300 shares by Thomas Catinazzo of Relay Therapeutics at 5.95 subject to Rule 16b-3
10/29/2024
9
Relay Therapeutics, Inc. CFO Thomas Catinazzo Sells 6,802 Shares
10/31/2024
10
Relay Therapeutics Issues Earnings Results
11/07/2024
11
Cornercap Investment Counsel Inc. Trims Holdings in Relay Therapeutics, Inc.
11/19/2024
12
Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround
11/20/2024

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.